Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
clinical trials
life sciences
national blog main
national top stories
3
×
san francisco blog main
san francisco top stories
3
×
biotech
boston
eli lilly
fda
indiana blog main
indiana top stories
new york blog main
new york top stories
rna interference
san diego blog main
san diego top stories
wisconsin blog main
wisconsin top stories
akcea therapeutics
alder biopharmaceuticals
alexion pharmaceuticals
alnylam pharmaceutials
alnylam pharmaceuticals
amgen
andrew fire
arrowhead pharmaceuticals
boehringer ingelheim
boulder/denver blog main
boulder/denver top stories
calcitonin gene-related peptide
chronic migraine
craig mello
david rind
deals
detroit blog main
detroit top stories
dicerna pharmaceuticals
What
gets
3
×
drug
fda
medicines
rnai
abandoning
afternoon
ago
alnylam
alnylam’s
amgen
approval
approved
baggage
candidates
class
companies
cuts
deal
developed
development
dicerna
free
head
history
interference
landmark
long
making
medicine
migraine
new
nod
ok
onpattro
pain
patisiran
pharma
pharmaceuticals
preventive
Language
Current search:
gets
×
" national top stories "
×
" san francisco top stories "
×
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines